MEK and the inhibitors: from bench to bedside

Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu

doi:10.1186/1756-8722-6-27

Back

MEK and the inhibitors: from bench to bedside

Journal article

Open access

Peer reviewed

MEK and the inhibitors: from bench to bedside

Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella and Delong Liu

Journal of hematology and oncology, Vol.6(1), pp.27-27

2013

DOI: 10.1186/1756-8722-6-27

PMCID: PMC3626705

PMID: 23587417

Files and links (1)

url

https://doi.org/10.1186/1756-8722-6-27View

Published (Version of record) Open Access

Abstract

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

Review

Details

Title: Subtitle: MEK and the inhibitors: from bench to bedside
Creators: Akintunde Akinleye - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA
Muhammad Furqan - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA
Nikhil Mukhi - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA
Pavan Ravella - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA
Delong Liu - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA
Resource Type: Journal article
Publication Details: Journal of hematology and oncology, Vol.6(1), pp.27-27
DOI: 10.1186/1756-8722-6-27
PMID: 23587417
PMCID: PMC3626705
NLM abbreviation: J Hematol Oncol
ISSN: 1756-8722
eISSN: 1756-8722
Publisher: BioMed Central
Language: English
Date published: 2013
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094525302771

Metrics

25 Record Views

240 Times Cited - Web of Science